Xcenda’s latest HTA Quarterly report shifts the spotlight to digital health technology, gene therapies for hemophilia and the EU’s new guidance on digital health tech.
Below are several articles featured in the newsletter:
- The Era of mHealth: A Global Perspective
- Emerging Gene Therapies for Hemophilia in the United States – Value Drivers in a Crystal Ball
- Regulatory and Market Access Impact in Europe of the Recent Medical Software Makers Guidance
To read Xcenda’s summer edition of HTA Quarterly, click here.